Progress in Targeting the Untouchables: Emerging Approaches for Hard-to-Drug Cancer Targets.

Innovation in drug development is an evolving concept that can take many forms, and is often confused with iteration, i.e., new versions of existing drug classes targeting familiar oncogenes. Yet meaningful innovation increasingly lies in translating approaches to historically ‘untouchable’ targets: transcription factors, tumor suppressors, and lineage-defining proteins, which have long resisted conventional pharmacological approaches. At the ESMO Targeted Anticancer…